Sun Pharma arm launches plaque psoriasis treatment drug in Japan
In June this year, they said its subsidiary possesses approval from the japanese government for Ilumya.
Signage is displayed at the Sun Pharma ceutical Industries Ltd. headquarters in Mumbai, India, on Thursday, May 2, 2019. (Photographer: Kanishka Sonthalia/Bloomberg)
Drug major it’s on Wednesday said its Japanese subsidiary has launched its specialty product Ilumya, indicated for treatment of plaque psoriasis in adult patients in Japan.
In June this year, they said its subsidiary possesses approval from the japanese government for Ilumya.
In a regulatory filing, Sun Pharmaceutical Industries said its “wholly-owned Japanese subsidiary has launched Ilumya injection 100 mg Syringe in Japan for the treatment of plaque psoriasis in adult patients who have an inadequate response to standard therapies”.
Junichi Nakamichi, Country Head, Sun Pharma Japan, said: “Ilumya is Sun Pharma’s first innovative drug to be launched within the Japanese market”.
Psoriasis may be a chronic immune disease that appears on the skin.
Shares of it were trading 0.34 per cent higher at Rs 512.20 apiece on BSE.
